Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,911 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C. Di Salvatore M, et al. Among authors: rossi e. Oncotarget. 2017 Mar 7;8(10):16887-16898. doi: 10.18632/oncotarget.14810. Oncotarget. 2017. PMID: 28129643 Free PMC article.
RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer.
Rossi E, Bagalà C, Inzani F, Leoncini E, Brunelli C, Lanza P, Basso M, Mattiucci GC, Cassano A, Rindi G, Barone C, Schinzari G. Rossi E, et al. In Vivo. 2017 Sep-Oct;31(5):833-840. doi: 10.21873/invivo.11136. In Vivo. 2017. PMID: 28882948 Free PMC article.
Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Schinzari G, Monterisi S, Pierconti F, Nazzicone G, Marandino L, Orlandi A, Racioppi M, Cassano A, Bassi P, Barone C, Rossi E. Schinzari G, et al. Among authors: rossi e. Anticancer Res. 2017 Nov;37(11):6453-6458. doi: 10.21873/anticanres.12100. Anticancer Res. 2017. PMID: 29061832
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M. Zizzari IG, et al. Among authors: rossi e. Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26. Cancer Immunol Res. 2018. PMID: 29700053
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma.
Rossi E, Maiorano BA, Pagliara MM, Sammarco MG, Dosa T, Martini M, Rindi G, Bria E, Blasi MA, Tortora G, Schinzari G. Rossi E, et al. Front Oncol. 2019 Apr 5;9:232. doi: 10.3389/fonc.2019.00232. eCollection 2019. Front Oncol. 2019. PMID: 31024839 Free PMC article.
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions.
Iacovelli R, Ciccarese C, Schinzari G, Maiorano BA, Rossi E, Pierconti F, Bassi PF, Bria E, Tortora G. Iacovelli R, et al. Among authors: rossi e. Crit Rev Oncol Hematol. 2019 Jul;139:83-86. doi: 10.1016/j.critrevonc.2019.05.005. Epub 2019 May 11. Crit Rev Oncol Hematol. 2019. PMID: 31112886 Review.
2,911 results